Though many sectors have been whacked by the Coronavirus-related hurdles in 2020, research and development of the gene editing technology known as CRISPR-Cas9 has continued mostly unabated. Scientists have reached some key milestones in their research into a number genetic blood disorders like sickle cell disease, beta thalassemia, and diabetes over the past couple of months. CRISPR has even managed to be utilized in brand new, low cost COVID-19 test kits, following emergency approval from the FDA.

Related ETF: ARK Genomic Revolution Multi-Sector ETF (ARKG)

To read this Market Insight, you’ll need to  sign in

If you don’t have a subscription,  sign up or start a free trial .